z-logo
Premium
Proposal for a histological scoring and grading system for non‐alcoholic fatty liver disease
Author(s) -
Mendler Michel Henry,
Kanel Gary,
Govindarajan Sugantha
Publication year - 2005
Publication title -
liver international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.873
H-Index - 110
eISSN - 1478-3231
pISSN - 1478-3223
DOI - 10.1111/j.1478-3231.2005.01052.x
Subject(s) - fatty liver , medicine , fibrosis , concordance , gastroenterology , grading (engineering) , cirrhosis , elevated alkaline phosphatase , portal hypertension , scoring system , pathology , disease , alkaline phosphatase , biology , ecology , biochemistry , enzyme
Aim/Background: The spectrum of histopathological features in non‐alcoholic fatty liver disease (NAFLD) has been well described. At least two scoring systems have been established. We propose here a system in which numerical scores are obtained using the different features. Methods: Twenty‐five cases of well‐defined NAFLD were idengified. Two pathologists blinded to idengifiers and clinical data independently scored the liver biopsies twice for portal fibrosis (PF: 0–6), lobular inflammation and necrosis (LIN: 0–3), Mallory bodies (MB: 0–3), hepatocyte ballooning (HB: 0–3), perisinusoidal fibrosis (PSF: 0–3) and fatty change (FC: 1–4). The κ statistic tested observer concordance. Non‐parametric measures of correlation and hierarchical cluster analysis were used to elaborate a grading system. Results: A broad spectrum of NAFLD was observed. Intra‐ and interobserver concordance was satisfactory. An activity score was created (AS: 0–12) as the sum of LIN, MB, HB and PSF, but not FC. A system for severity of NAFLD was developed: Grade 1 (PF: 0–2 and AS: 0–4), Grade 2 (PF: 3 or AS: 5–7) and Grade 3 (PF: 4–6 or AS: 8–12). Diabetes, elevated alkaline phosphatase and decreased platelets were associated with advanced grade. Conclusions: This simple, reproducible NAFLD score produces a three‐tier severity grade. This numerical system may prove useful in assessing disease severity and interval changes.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here